To address the goals of MiND, a highly multi- and interdisciplinary team is essential. MiND represents a unique mix of people with skills and expertise in:

• (paediatric and adult) neuropsychiatry 
• neuropsychology 
• neuroimaging
• neurochemistry
• genetics, epigenetics, genomics
• animal models and technical assay development
• clinical pharmacology
• bioinformatics and biostatistics
• ethics
• education and training
• valorisation and business skills
• EU project management

Synergy within the network through exploitation of complementarities is a key issue in MiND, and the whole structure of the training programme emphasizes this interdisciplinarity. Synergy can be expected in several dimensions: (1) from bench to bedside: we find this intersectoral dimension so important that we have involved both clinically trained and basic researchers from almost all academic sites; (2) from molecule to man and population; (3) from a basic understanding of disease etiology to (first steps towards) the use of research findings in clinical diagnosis, prognosis and pharmacological and non-pharmacological treatment: our research and training programme resembles an intersectoral pipeline that can be implemented to reduce the gap between science and the clinic; (4) from academia to private sectors: placed in both sectors, our ESRs will become bridge-builders to advance science and therapy.

MiND has 12 beneficiaries and 9 partners. The consortium members have a proven track record of successful collaborations – including academic and private sector parties – showing their strong commitment to work closely together to achieve project goals related to etiology and treatment of neurodevelopmental disorders.